CGM Use Improved Glycemia During Pregnancy in T1DM Tags hBA1c Continuous glucose monitoring (CGM) Read more about CGM Use Improved Glycemia During Pregnancy in T1DM
SGLT2 Inhibitors Were Linked to Lower Epilepsy Risk in T2DM Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Were Linked to Lower Epilepsy Risk in T2DM
GLP-1RAs Showed Favorable Liver Outcomes Signal in T2DM Tags MASLD/MASH GLP-1 agonists Read more about GLP-1RAs Showed Favorable Liver Outcomes Signal in T2DM
Finerenone Triple Therapy Slowed eGFR Decline in DKD Tags Diabetic Nephropathy SGLT-2 Inhibitor Read more about Finerenone Triple Therapy Slowed eGFR Decline in DKD
Injectable Semaglutide, Efpeglenatide Led MACE Profiles in T2DM Tags Coronary artery disease Stroke GLP-1 agonists Read more about Injectable Semaglutide, Efpeglenatide Led MACE Profiles in T2DM
SGLT2 Inhibitors Showed Sustained Weight Reduction in PTDM Tags SGLT-2 Inhibitor hBA1c Read more about SGLT2 Inhibitors Showed Sustained Weight Reduction in PTDM
Continuous Antibiotic Infusion Improved Tissue Target Attainment in iDFUs Tags Diabetic foot. Read more about Continuous Antibiotic Infusion Improved Tissue Target Attainment in iDFUs
Gut Microbiota Metabolites Linked to Diabetic Kidney Disease in T2DM Tags CKD Diabetic Nephropathy Read more about Gut Microbiota Metabolites Linked to Diabetic Kidney Disease in T2DM
Synthetic Semaglutide Showed Noninferior Glycemic Control vs Reference Semaglutide Tags FBS GLP-1 agonists PLBS hBA1c Read more about Synthetic Semaglutide Showed Noninferior Glycemic Control vs Reference Semaglutide
Canagliflozin Renal Benefits Were Similar Across 100 mg and 300 mg Doses Tags SGLT-2 Inhibitor Read more about Canagliflozin Renal Benefits Were Similar Across 100 mg and 300 mg Doses
